APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension (PAH) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook and Growth Opportunities 2026

26 December 2025198 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension (PAH) Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension (PAH) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Arterial Hypertension (PAH) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Arterial Hypertension (PAH) Drugs market include Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Berlin Cures, Daiichi Sankyo, Eiger BioPharmaceuticals, Glaxosmithkline and Northern Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Arterial Hypertension (PAH) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Arterial Hypertension (PAH) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Arterial Hypertension (PAH) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Arterial Hypertension (PAH) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Company

Actelion Pharmaceuticals

Aires Pharmaceuticals

Arena Pharmaceuticals

AstraZeneca

Berlin Cures

Daiichi Sankyo

Eiger BioPharmaceuticals

Glaxosmithkline

Northern Therapeutics

Reata Pharmaceuticals

United Therapeutics

Bayer Healthcare

Pfizer

Merck

Novartis

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type

Injectables

Inhalation

Oral Administration

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application

Hospitals

Clinics

Other

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pulmonary Arterial Hypertension (PAH) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pulmonary Arterial Hypertension (PAH) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Arterial Hypertension (PAH) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Arterial Hypertension (PAH) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Arterial Hypertension (PAH) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Arterial Hypertension (PAH) Drugs industry.

Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pulmonary Arterial Hypertension (PAH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pulmonary Arterial Hypertension (PAH) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends Table 2. Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers Table 3. Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges Table 4. Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Company (W Pcs) & (2021-2026) Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Company, Product Type & Application Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injectables Table 18. Significant Companies of Inhalation Table 19. Significant Companies of Oral Administration Table 20. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Pcs) Table 21. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type (2021-2026) & (W Pcs) Table 22. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type (2027-2032) & (W Pcs) Table 23. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type (2021-2026) Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Other Table 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Pcs) Table 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application (2021-2026) & (W Pcs) Table 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application (2027-2032) & (W Pcs) Table 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application (2021-2026) Table 42. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application (2027-2032) Table 43. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Table 44. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2026) & (W Pcs) Table 45. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2021-2026) Table 46. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032) & (W Pcs) Table 47. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2027-2032) Table 48. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Region (2021-2026) Table 51. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Region (2027-2032) Table 53. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Average Price (US$/Pcs) by Region (2021-2026) Table 54. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Average Price (US$/Pcs) by Region (2027-2032) Table 55. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Table 56. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 58. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2026) Table 59. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs) Table 60. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2027-2032) Table 61. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Market Share by Country (2027-2032) Table 65. Actelion Pharmaceuticals Company Information Table 66. Actelion Pharmaceuticals Business Overview Table 67. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 68. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 69. Actelion Pharmaceuticals Recent Development Table 70. Aires Pharmaceuticals Company Information Table 71. Aires Pharmaceuticals Business Overview Table 72. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 73. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 74. Aires Pharmaceuticals Recent Development Table 75. Arena Pharmaceuticals Company Information Table 76. Arena Pharmaceuticals Business Overview Table 77. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 78. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 79. Arena Pharmaceuticals Recent Development Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 83. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 84. AstraZeneca Recent Development Table 85. Berlin Cures Company Information Table 86. Berlin Cures Business Overview Table 87. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 88. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 89. Berlin Cures Recent Development Table 90. Daiichi Sankyo Company Information Table 91. Daiichi Sankyo Business Overview Table 92. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 93. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 94. Daiichi Sankyo Recent Development Table 95. Eiger BioPharmaceuticals Company Information Table 96. Eiger BioPharmaceuticals Business Overview Table 97. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 98. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 99. Eiger BioPharmaceuticals Recent Development Table 100. Glaxosmithkline Company Information Table 101. Glaxosmithkline Business Overview Table 102. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 103. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 104. Glaxosmithkline Recent Development Table 105. Northern Therapeutics Company Information Table 106. Northern Therapeutics Business Overview Table 107. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 108. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 109. Northern Therapeutics Recent Development Table 110. Reata Pharmaceuticals Company Information Table 111. Reata Pharmaceuticals Business Overview Table 112. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 113. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 114. Reata Pharmaceuticals Recent Development Table 115. United Therapeutics Company Information Table 116. United Therapeutics Business Overview Table 117. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 118. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 119. United Therapeutics Recent Development Table 120. Bayer Healthcare Company Information Table 121. Bayer Healthcare Business Overview Table 122. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 123. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 124. Bayer Healthcare Recent Development Table 125. Pfizer Company Information Table 126. Pfizer Business Overview Table 127. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 128. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 129. Pfizer Recent Development Table 130. Merck Company Information Table 131. Merck Business Overview Table 132. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 133. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 134. Merck Recent Development Table 135. Novartis Company Information Table 136. Novartis Business Overview Table 137. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 138. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 139. Novartis Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List Table 143. Pulmonary Arterial Hypertension (PAH) Drugs Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Image Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (2021-2032) & (W Pcs) Figure 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injectables Image Figure 10. Inhalation Image Figure 11. Oral Administration Image Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Pcs) Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Other Image Figure 21. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Pcs) Figure 22. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Figure 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Pulmonary Arterial Hypertension (PAH) Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Injectables
  • Inhalation
  • Oral Administration
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Berlin Cures
  • Daiichi Sankyo
  • Eiger BioPharmaceuticals
  • Glaxosmithkline
  • Northern Therapeutics
  • Reata Pharmaceuticals
  • United Therapeutics
  • Bayer Healthcare
  • Pfizer
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pulmonary Arterial Hypertension (PAH) Drugs Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints
3 Pulmonary Arterial Hypertension (PAH) Drugs Market by Company
  1. 3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Pulmonary Arterial Hypertension (PAH) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Pulmonary Arterial Hypertension (PAH) Drugs Company Product Type and Application
  8. 3.8 Global Pulmonary Arterial Hypertension (PAH) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pulmonary Arterial Hypertension (PAH) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pulmonary Arterial Hypertension (PAH) Drugs Market by Type
  1. 4.1 Pulmonary Arterial Hypertension (PAH) Drugs Type Introduction
  2. 4.1.1 Injectables
  3. 4.1.2 Inhalation
  4. 4.1.3 Oral Administration
  5. 4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type
  6. 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type
  10. 4.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type (2021-2032)
5 Pulmonary Arterial Hypertension (PAH) Drugs Market by Application
  1. 5.1 Pulmonary Arterial Hypertension (PAH) Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application
  6. 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application
  10. 5.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application (2021-2032)
6 Pulmonary Arterial Hypertension (PAH) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Arterial Hypertension (PAH) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Actelion Pharmaceuticals
  2. 8.1.1 Actelion Pharmaceuticals Company Information
  3. 8.1.2 Actelion Pharmaceuticals Business Overview
  4. 8.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  6. 8.1.5 Actelion Pharmaceuticals Recent Developments
  7. 8.2 Aires Pharmaceuticals
  8. 8.2.1 Aires Pharmaceuticals Company Information
  9. 8.2.2 Aires Pharmaceuticals Business Overview
  10. 8.2.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  12. 8.2.5 Aires Pharmaceuticals Recent Developments
  13. 8.3 Arena Pharmaceuticals
  14. 8.3.1 Arena Pharmaceuticals Company Information
  15. 8.3.2 Arena Pharmaceuticals Business Overview
  16. 8.3.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  18. 8.3.5 Arena Pharmaceuticals Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Berlin Cures
  26. 8.5.1 Berlin Cures Company Information
  27. 8.5.2 Berlin Cures Business Overview
  28. 8.5.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  30. 8.5.5 Berlin Cures Recent Developments
  31. 8.6 Daiichi Sankyo
  32. 8.6.1 Daiichi Sankyo Company Information
  33. 8.6.2 Daiichi Sankyo Business Overview
  34. 8.6.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  36. 8.6.5 Daiichi Sankyo Recent Developments
  37. 8.7 Eiger BioPharmaceuticals
  38. 8.7.1 Eiger BioPharmaceuticals Company Information
  39. 8.7.2 Eiger BioPharmaceuticals Business Overview
  40. 8.7.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  42. 8.7.5 Eiger BioPharmaceuticals Recent Developments
  43. 8.8 Glaxosmithkline
  44. 8.8.1 Glaxosmithkline Company Information
  45. 8.8.2 Glaxosmithkline Business Overview
  46. 8.8.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  48. 8.8.5 Glaxosmithkline Recent Developments
  49. 8.9 Northern Therapeutics
  50. 8.9.1 Northern Therapeutics Company Information
  51. 8.9.2 Northern Therapeutics Business Overview
  52. 8.9.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  54. 8.9.5 Northern Therapeutics Recent Developments
  55. 8.10 Reata Pharmaceuticals
  56. 8.10.1 Reata Pharmaceuticals Company Information
  57. 8.10.2 Reata Pharmaceuticals Business Overview
  58. 8.10.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  60. 8.10.5 Reata Pharmaceuticals Recent Developments
  61. 8.11 United Therapeutics
  62. 8.11.1 United Therapeutics Company Information
  63. 8.11.2 United Therapeutics Business Overview
  64. 8.11.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  66. 8.11.5 United Therapeutics Recent Developments
  67. 8.12 Bayer Healthcare
  68. 8.12.1 Bayer Healthcare Company Information
  69. 8.12.2 Bayer Healthcare Business Overview
  70. 8.12.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  72. 8.12.5 Bayer Healthcare Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  84. 8.14.5 Merck Recent Developments
  85. 8.15 Novartis
  86. 8.15.1 Novartis Company Information
  87. 8.15.2 Novartis Business Overview
  88. 8.15.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  90. 8.15.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Analysis
  2. 9.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Arterial Hypertension (PAH) Drugs Sales Mode & Process
  6. 9.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors
  9. 9.2.3 Pulmonary Arterial Hypertension (PAH) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst